Subsequent investigations revealed that ALYREF promotes platinum resistance in ovarian cancer cells by activating the Wnt/β-Catenin pathway via the NSUN2/ALYREF/LGR4 signaling axis. This evidence concerns the gene NSUN2 and ovarian cancer.